


Labomar acquires Finnish company Pharmia, strengthening its position in Northern Europe

Group's fifth acquisition in six years, supported by Charterhouse Capital Partners, as it consolidates its international nutraceuticals and medical devices leadership. Pharmia is a European dietary supplements and medical devices CDMO leader, with a strong presence in Finland, Sweden, Denmark and Norway

Istrana (Italy), October 2, 2025 - **Labomar S.p.A.**, a leading international nutraceutical company specialising in the research, development, and contract manufacturing of dietary supplements, medical devices, foods for special medical purposes, and cosmetics, **announces the acquisition of 97.85% of the share capital of Pharmia Holding Oy**, Finland's leading CDMO (Contract Development and Manufacturing Organisation). Pharmia specialises in the development and production of dietary supplements, probiotics and medical devices. Labomar is backed by leading European private equity firm Charterhouse Capital Partners.

Founded in 1993, Pharmia now employs 85 people at its headquarters in Tuusula, just a few kilometres from Helsinki Airport, and operates a **5,000 m² integrated production site** with an **annual capacity of approx. 485 million tablets and capsules, and 37,000 litres of liquids**. With **2024 turnover of €20 million**, further visible growth in 2025, a leading position in the Nordic countries (Finland, Sweden, Denmark and Norway) and extensive expertise in the development of probiotics and medical devices, the company consistently invests 5% of its turnover in research and development, continuing to strengthen operational efficiency and confirming itself as a strategic partner for numerous international players.

The transaction is Labomar Group's fifth acquisition in six years, highlighting the company's growth strategy, which has always been focused on innovation, the development of advanced health solutions and a diversified global presence. The acquisition of Pharmia Holding Oy will enable the company to continue to expand its expertise in research and development, particularly in medical devices and probiotics, and to benefit from a central position in a high-potential region, which has estimated* CAGR growth of 5-7% over the 2024-2029 period. Expanding into the Nordic market will also enable Labomar to consolidate its international presence in nutraceuticals and medical devices, expanding its customer base and generating new synergies in terms of innovation and product development.



The transaction was finalised on September 25, with Pharmia's current management remaining within the company and continuing to hold 2.15% of the company's capital.


*"Welcoming Pharmia into our Group is a source of great satisfaction and represents a key step in our vision for international growth," stated **Walter Bertin, founder and Chief Executive Officer of Labomar**. "We have found a team that shares our approach to innovation and quality, allowing us to strengthen in a market full of opportunities, in which we can build lasting relationships with major players and accompany them in attaining increasingly advanced solutions. In addition, Pharmia's solid management structure and production capacity will enable us to rapidly integrate activities and accelerate the development trajectory we are charting at a pan-European level".*

Antonio Di Lorenzo, Partner at Charterhouse Capital Partners, added, *"We are very pleased to have supported the continued growth of Labomar over the past few years, both through organic expansion and through M&A opportunities, a key pillar of our value creation strategy."*

Petteri Laaksomo, CEO of Pharmia Holding Oy, commented, *"We are thrilled to be part of the Labomar family. This acquisition marks a strategic step forward in our mission to expand our footprint in the Nordic region and strengthen our capabilities in the development of high-quality nutraceuticals and medical devices. Labomar's expertise and values align seamlessly with ours, and together we look forward to driving innovation and delivering even greater value to our partners and customers".*

Labomar continues to pursue its acquisition-led growth strategy which begun in 2019, supported by Charterhouse Capital Partners and its value-creation capabilities, with the acquisition of Importfab (now **Labomar Canada**), which operates in the North American pharmaceutical, cosmetic and nutraceutical market; in 2020 with the entry of the **Welcare Group**, based in Orvieto (Umbria) and specialising in medical devices for the prevention, hygiene and treatment of skin infections and lesions; of **Labiotre**, located in Tavarnelle Val di Pesa (Tuscany) and dedicated to the production of plant extracts and softgel dietary supplements; and finally of **Laboratorios Entema**, a Barcelona-based company specialising in the contract manufacturing of cosmetics, medical devices and dietary supplements.

The acquisition transaction was coordinated by an internal team comprising Claudio De Nadai (Board Member), Marco Malaguti (Chief Strategy Officer) and Nicola Tomasini (Group Chief Financial Officer).



Labomar was assisted in the acquisition by BModel as Corporate Advisor, which coordinated the professional activities dedicated to Business Due Diligence, carried out by Boston Consulting Group, for the Financial & Tax Due Diligence by EY Epyon, in addition to Legal Due Diligence, and the drafting of the legal and contractual documents by PwC Legal.

**Boston Consulting Group report*

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso, Italy) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, pharmaceuticals, foods for special medical purposes and cosmetics for third parties. Over more than 25 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard.

The company boasts a well-structured and cutting-edge research and development department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Following the acquisitions of Labomar Canada, the Welcare Group, Labiotre Srl and Laboratorios Entema, in addition to the undertaking of a stake in Sphera, Labomar focused on maximising the synergies among the various companies, pooling resources and expertise to expand its product portfolio, enter new markets and streamline certain processes, including through the best practices brought by each of the Group companies.

After a time on the EGM segment of the stock market, which ended in September 2023, Labomar's shareholder structure now includes Charterhouse Capital Partners, one of the oldest private equity firms operating in Europe. This is once again testament to the Company's attention on overseeing the market and planning its growth.

Labomar wholeheartedly believes in a business system based on sustainability and a real concern for people, the environment and the community. It therefore by 2020 had gained Benefit Company status and later obtained B-Corp™ Certification. This is testament to the Company's decision to join a global movement of enterprises meeting elevated social and environmental impact standards.

For further information:
Labomar Press Office

THANAI Communication Advisors

Thanai Bernardini - +39.335.7245418 - me@thanai.it

Chiara Andretta - +39.347.0682566 - chiara.andretta@thanai.it

Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it